Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2020-01-14
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of cytoreductive prostatectomy in treating
patients with newly diagnosed prostate cancer that has spread from the primary site to other
places in the body. Cytoreductive prostatectomy is a type of surgery that removes the
prostate and as much of the tumor as possible. When combined with hormone therapy, robotic
assisted radical prostatectomy (RARP) or conventional open retropubic radical prostatectomy
(RRP) may prolong survival in patients with prostate cancer that has spread.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey